VSIR and prostate carcinoma: Similarly, Gao et al. found that VISTA expression was elevated after anti-CTLA4 therapy in patients with prostate cancer, suggesting that elevated VISTA expression is a compensatory event in the setting of ipilimumab therapy [11].